Invest in a Healthier World:
Backing Innovation that Saves Lives
At HeartForce™, we are radically transforming the detection of coronary artery disease. We believe that early detection of cardiovascular disease saves lives and helps reduce healthcare costs. That’s why we’re shaping the future of cardiac diagnostics to make it possible. As an investor, you’re not just backing a product; you’re helping shift the paradigm in preventive medicine.
Our vision is bold but clear: we are building a future where the early detection of coronary artery disease is accessible, accurate, affordable, and patient-friendly.
Fast.
Low cost.
Secure data handling.
Supported by clinical validation, cutting-edge AI, and a strong commitment to regulatory excellence — including EUDAMED registration and the assignment of our Single Registration Number (SRN) — we are advancing scalable solutions for earlier detection of cardiovascular disease.
Our mission is to transform cardiovascular care by enabling accurate, accessible and patient-friendly heart screening, beginning with coronary artery disease (CAD), the world’s leading cause of death¹.
This section provides a detailed view of our business performance and future direction. Whether you’re a potential investor or long-standing partner, you’ll find the information needed to support informed and purposeful investment decisions.
Our Founder's Story
Kay Jessel
Founder & Shareholder at HeartForce
From Personal Loss to Purpose: Why We Built HeartForce
Born and raised in Hamburg, Germany, I began my career in investment banking before co-founding a Swiss-German venture capital firm. On paper, everything looked perfect.
But my true passion had always been medicine, helping people directly and meaningfully.
That changed in 2010, when my father suffered a second heart attack and passed away. With my own high cholesterol and family history, I quickly realized how quietly cardiovascular risk can build over time. What was once a statistic became reality.
In 2016, I made the decision to dedicate my energy to fighting cardiovascular disease. That journey led me to HeartForce. Together with my partner Beat Naegeli, we transformed the company with a clear mission: early risk detection of coronary artery disease.
Since then, we’ve invested over $18 million and a decade of research into developing our core system, the EMCR-Score™. By analyzing the heart’s mechanical signals with AI-powered seismocardiography, we can identify CAD risk, even before symptoms appear.
What matters most to me is not the technology itself, but what it enables:
giving people a chance to act before catastrophe strikes.
Every day, we are driven by a simple reality:
- For many, a fatal heart attack is the first symptom.
- There is still no routine screening for asymptomatic individuals.
- Coronary artery disease remains the world’s leading cause of death.
Our goal is deeply personal:
to help ensure fewer families receive the call that changed my life.
This journey began with loss but continues with purpose, and a mission to detect risk earlier and change lives.
Kay Jessel
Founder & Shareholder at Heart Force AG
Lab to Market
Follow our journey from technology development through clinical validation and international regulatory processes. Discover how our mission grows into a market-ready solution ready for adoption worldwide.
Investor Inquiries
If you would like to know more about our business plan, revenue model and investment thesis, future product pipeline of other strategic updates.